Evidence map›Paper›PMID 41323250›Full record

ArticleJournal of mass spectrometry and advances in the clinical lab2025

Adapting a commercial sample extraction protocol for biosafety level 3/4 compatible plasma metabolomics analysis.

J Brandsma, J W Thompson, K L Schully, J G Chenoweth, P Genzor, S Krishnan, D A Striegel, L St John-Williams, A Moseley, G Oduro and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of mass spectrometry and advances in the clinical lab, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

J BrandsmaAustere Environments Consortium for Enhanced Sepsis Outcomes, Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD, USA.
J W ThompsonDuke University, School of Medicine, Durham, NC, USA.
K L SchullyAustere Environments Consortium for Enhanced Sepsis Outcomes, Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD, USA.
J G ChenowethAustere Environments Consortium for Enhanced Sepsis Outcomes, Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD, USA.
P GenzorAustere Environments Consortium for Enhanced Sepsis Outcomes, Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD, USA.
S KrishnanAustere Environments Consortium for Enhanced Sepsis Outcomes, Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD, USA.
D A StriegelAustere Environments Consortium for Enhanced Sepsis Outcomes, Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD, USA.
L St John-WilliamsDuke University, School of Medicine, Durham, NC, USA.
A MoseleyDuke University, School of Medicine, Durham, NC, USA.
G OduroKomfo Anokye Teaching Hospital, Kumasi, Ghana.
N AdamsInfectious Diseases Directorate, Naval Medical Research Command, Silver Spring, MD, USA.
T VanthaTakeo Provincial Referral Hospital, Takeo, Cambodia.
E L TsalikDuke University, School of Medicine, Durham, NC, USA.
C W WoodsDuke University, School of Medicine, Durham, NC, USA.
D V ClarkAustere Environments Consortium for Enhanced Sepsis Outcomes, Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Severe infections and sepsis significantly impact military operational readiness and costs through loss of duty days, high treatment rates, and medical evacuations. Early diagnosis is critical for preventing sepsis progression and mortality, but it requires validated biomarkers to guide clinical decision-making. Study protocols for host biomarker discovery in infections usually require inactivation of high-risk pathogens prior to sample analysis, which limits the utility of metabolomics assays designed for untreated samples. Methods: Matched blood plasma aliquots obtained from an international, observational sepsis cohort were analyzed to quantify metabolites following the commercial Absolute Results: Levels of agreement between the unmodified Absolute Conclusions: This study extends the applicability of commercial metabolomics assays designed for untreated samples by improving their suitability for high-risk infectious disease studies. Differences in metabolite extraction efficiencies and detection rates, as well as data harmonization strategies, should be considered if results from both protocols are to be combined.

Indexed as

BiosafetyHigh-risk pathogensInfectious diseasesMetabolomicsSample extraction

Identifiers

PMID41323250
PMCPMC12661157

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.